Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PMV Pharmaceuticals, Inc. Director's Dealing 2022

Feb 28, 2022

34350_dirs_2022-02-28_33a554ac-dd79-4ee2-bf5b-72afeacd562d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2022-02-10

Reporting Person: Kung Winston (COO, CFO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-10 Employee Stock Option (right to buy) $16.29 A 104400 Acquired 2032-02-10 Common Stock (104400) Direct

Footnotes

F1: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.